Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis

JAMA Oncol. 2015 Sep;1(6):836-8. doi: 10.1001/jamaoncol.2015.0736.

Authors

Sébastien Héritier¹, Mathilde Jehanne², Guy Leverger¹, Jean-François Emile³, Jean-Claude Alvarez⁴, Julien Haroche⁵, Jean Donadieu¹

Affiliations

¹ Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France.
² Department of Pediatric Hematology and Oncology, Felix Guyon Hospital, Saint-Denis Réunion, France.
³ Pathology Department, Ambroise Paré Hospital, APHP, Boulogne, France.
⁴ Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, APHP, Garches, France.
⁵ Department of Internal Medicine & French Reference Center for Rare Auto-immune & Systemic Diseases, Pitié-Salpêtrière Hospital, APHP, Paris, France.

PMID: 26180941
DOI: 10.1001/jamaoncol.2015.0736

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / antagonists & inhibitors*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Female
Genetic Predisposition to Disease
Histiocytosis, Langerhans-Cell / diagnosis
Histiocytosis, Langerhans-Cell / drug therapy*
Histiocytosis, Langerhans-Cell / enzymology
Histiocytosis, Langerhans-Cell / genetics
Humans
Indoles / pharmacokinetics
Indoles / therapeutic use*
Infant
Molecular Targeted Therapy
Mutation
Phenotype
Protein Kinase Inhibitors / pharmacokinetics
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins B-raf / metabolism
Remission Induction
Sulfonamides / pharmacokinetics
Sulfonamides / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome
Vemurafenib

Substances

Biomarkers, Tumor
Indoles
Protein Kinase Inhibitors
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf